SOLARA ACTIVE PHARMA SCIENCES
|
SOLARA ACTIVE PHARMA SCIENCES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | -157.61 | -6.16 | -16.15 | 61.62 | 42.69 |
| CEPS(Rs) | -118.69 | 22.77 | 13.83 | 84.65 | 71.63 |
| DPS(Rs) | - | - | - | 7.00 | 2.00 |
| Book NAV/Share(Rs) | 258.96 | 416.43 | 423.30 | 441.06 | 366.93 |
| Tax Rate(%) | -16.08 | 50.36 | 36.02 | 0.07 | 0.34 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | -7.38 | 9.27 | 6.31 | 23.87 | 19.63 |
| EBIT Margin(%) | -29.74 | 3.13 | -1.25 | 18.92 | 14.59 |
| Pre Tax Margin(%) | -37.89 | -3.10 | -7.18 | 13.70 | 8.69 |
| PAT Margin (%) | -43.99 | -1.54 | -4.60 | 13.69 | 8.66 |
| Cash Profit Margin (%) | -35.97 | 6.16 | 4.26 | 20.41 | 15.79 |
| Performance Ratios | |||||
| ROA(%) | -21.93 | -0.78 | -2.13 | 9.34 | 5.57 |
| ROE(%) | -46.64 | -1.47 | -3.75 | 17.23 | 12.48 |
| ROCE(%) | -17.29 | 1.79 | -0.67 | 15.34 | 11.73 |
| Asset Turnover(x) | 0.50 | 0.51 | 0.46 | 0.68 | 0.64 |
| Sales/Fixed Asset(x) | 0.69 | 0.80 | 0.73 | 0.98 | 0.91 |
| Working Capital/Sales(x) | -2.83 | 16.71 | 7.21 | 6.01 | -22.83 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.45 | 1.26 | 1.37 | 1.02 | 1.09 |
| Receivable days | 125.38 | 129.77 | 140.08 | 80.18 | 71.15 |
| Inventory Days | 129.95 | 143.29 | 125.26 | 64.87 | 68.16 |
| Payable days | 140.30 | 134.61 | 163.35 | 132.36 | 140.33 |
| Valuation Parameters | |||||
| PER(x) | - | - | - | 22.63 | 10.38 |
| PCE(x) | -2.89 | 13.29 | 44.32 | 15.18 | 5.70 |
| Price/Book(x) | 1.44 | 0.79 | 1.57 | 3.16 | 1.21 |
| Yield(%) | - | - | - | 0.50 | 0.45 |
| EV/Net Sales(x) | 1.81 | 1.51 | 2.66 | 3.35 | 1.39 |
| EV/Core EBITDA(x) | -25.96 | 13.90 | 33.72 | 13.07 | 6.41 |
| EV/EBIT(x) | -6.08 | 48.07 | -213.14 | 17.71 | 9.54 |
| EV/CE(x) | 1.21 | 0.87 | 1.32 | 2.47 | 1.03 |
| M Cap / Sales | 1.04 | 0.82 | 1.89 | 3.10 | 0.90 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -10.73 | 13.83 | -21.56 | 22.33 | -4.68 |
| Core EBITDA Growth(%) | -157.41 | 56.45 | -75.89 | 44.49 | 23.06 |
| EBIT Growth(%) | -947.28 | 385.97 | -105.17 | 58.70 | 28.46 |
| PAT Growth(%) | -2,448.13 | 61.83 | -126.33 | 93.29 | 70.70 |
| EPS Growth(%) | -2,458.12 | 61.86 | -126.21 | 44.36 | 84.84 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 1.07 | 0.67 | 0.67 | 0.38 | 0.72 |
| Current Ratio(x) | 0.63 | 1.08 | 1.17 | 1.34 | 0.92 |
| Quick Ratio(x) | 0.34 | 0.57 | 0.62 | 0.97 | 0.54 |
| Interest Cover(x) | -3.65 | 0.50 | -0.21 | 3.62 | 2.48 |
| Total Debt/Mcap(x) | 0.75 | 0.85 | 0.43 | 0.12 | 0.59 |
Compare Financial Ratios of peers of SOLARA ACTIVE PHARMA SCIENCES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SOLARA ACTIVE PHARMA SCIENCES | ₹3,290.8 Cr | -5.1% | -16.3% | 122.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹441,838.0 Cr | 1% | 4.6% | 47.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹156,107.0 Cr | 1% | -3.2% | 59.3% | Stock Analytics | |
| CIPLA | ₹120,270.0 Cr | -1.1% | -0.3% | 20.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹113,077.0 Cr | 2.2% | 12.1% | 21.6% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹96,553.2 Cr | -2.7% | 0.8% | 43.8% | Stock Analytics | |
SOLARA ACTIVE PHARMA SCIENCES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SOLARA ACTIVE PHARMA SCIENCES | -5.1% |
-16.3% |
122.4% |
| SENSEX | -2.1% |
-2% |
11.3% |
You may also like the below Video Courses
